



# Association Between Bone Mineral Density and Type 1 Diabetes Mellitus: A Meta-analysis Of Observational Studies


Chirag S Shah<sup>1</sup>, Viral N Shah<sup>2</sup>, Nishkarsh Likhari<sup>1</sup>, Raj Kumar Mothe<sup>1</sup>, Raju Kanukula<sup>1</sup>, Amit Dang<sup>1</sup>

<sup>1</sup>MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India; <sup>2</sup>Adult Clinic, Barbara Davis Center for Diabetes, University of Colorado, Colorado CO, 1775, USA

## INTRODUCTION

- Various studies have reported that Bone Mineral Density (BMD) is reduced in patients with Type 1 Diabetes Mellitus (T1DM)<sup>1</sup>
- In fact, osteopenia has been described in T1DM patients long ago, even before the availability of modern techniques to measure BMD<sup>1</sup>
- However, the data is not consistent among all the reported studies<sup>1</sup>
- Potential mechanisms leading to osteoporosis in patients with T1DM<sup>1</sup>

### Autoimmune destruction of beta cells in type 1 diabetes



## OBJECTIVE


To perform a meta-analysis to estimate the difference in BMD between T1DM and non-diabetic populations

## METHODOLOGY

- Eligibility Criteria**
  - Cases: T1DM patient (of any age group)
  - Control: Healthy subject (non diabetic)
  - BMD measurement:
    - BMD was measured by dual energy X-ray absorptiometry (DXA)
    - BMD measurements were expressed as an absolute value in g/cm<sup>2</sup>
  - Study design: All observational studies were included (case controlled and cohort studies)
- Literature Search:** Performed in PubMed and EMBASE for cross-sectional cohort and case-control studies pertaining to T1DM and osteoporosis
- Additional searches were conducted to include research abstracts, cross references and bibliography of individual articles
- Studies up to January 2014 were included
- Key Words:**
  - Type 1 Diabetes Mellitus
  - Bone Mineral Density
  - Dual energy X-ray absorptiometry (DEXA)
  - Assessment of studies was performed by two independent researchers
- A random effects was used to pool data in case of substantial heterogeneity among studies
- Heterogeneity and publication bias were assessed

## RESULTS

### PRISMA Flow Diagram




## RESULTS

- Number of studies included: 48
- Number of patients involved:
  - Cases: 2,885
  - Controls: 4,814
- Meta-analysis showed that BMD in T1DM patients was significantly lower at many regions
- Pooled mean differences of BMD in patients with T1DM when compared with control:
  - Hip region:**
    - Women: -0.43 (95% Confidence interval [CI]: -0.69 to -0.17)
    - Men: -0.25 (95% CI: -0.50 to -0.005)
  - Spine region:**
    - Men: -0.30 (95% CI: -0.47 to -0.13)
  - Forearm region:**
    - Women: -0.21 (95% CI: -0.43 to 0.00)
    - Femoral neck: No significant difference was found in BMD (in both men and women)

- Pooled mean differences of site-wise BMD in patients with T1DM when compared with control:


Site	Gender	Number of studies	Effect size (SMD)	95% CI	P value	I <sup>2</sup> value
Spine	Male	9	-0.308	0.479 to -0.136	0.001*	0 %
	Female	17	0.101	0.292 to 0.104	0.353	69 %
Hip	Male	4	-0.254	0.502 to -0.005	0.045*	63 %
	Female	7	-0.435	0.695 to -0.174	0.001*	51 %
Femoral neck	Male	8	0.077	0.574 to 0.727	0.818	98 %
	Female	11	0.170	0.779 to 1.119	0.725	93 %
Forearm	Male	3	-0.069	0.332 to 0.195	0.609	0 %
	Female	4	-0.218	0.437 to 0.002	0.052	49 %

- Hip BMD in Male Subjects with Type 1 diabetes mellitus compared to healthy subjects



Fixed effect= SMD -0.254, 95% CI -0.502 to -0.005 (p value = 0.045), I<sup>2</sup>= 51 %


- Hip BMD in Female Subjects with Type 1 diabetes mellitus compared to healthy subjects



Random effect model = SMD -0.435, 95% CI -0.695 to -0.174 (P value= 0.001), I<sup>2</sup>= 62.97

## DISCUSSION

- Proposed pathogenic mechanisms behind reduced BMD in T1DM patients:<sup>2</sup>
  - Hyperglycemia
  - Autoimmune inflammation
  - Increased PPAR- $\gamma$  activity increased marrow adiposity
  - Hypoinsulinemia and hypoamylinemia
  - Deficit of IGF-I and Vitamin D
  - Nonenzymatic glycosylation of type 1 collagen with subsequent formation of AGEs (advanced glycation end products)
- Factors influencing the bone in T1DM patients
  - Age of onset
    - Prepubertal onset T1DM: decreased bone formation and inadequate accrual peak bone mass osteopenia<sup>3</sup>
  - Gender
    - Men with T1DM are more prone to osteopenia than women<sup>4</sup>
    - Estrogen adequacy and/or use of estrogen-based oral contraceptive pills might be the reason for higher bone mass in women compared to men<sup>4</sup>
  - BMI
    - Lower BMI is associated with higher incidence of osteoporosis<sup>5</sup>
    - Adipose tissue  $\rightarrow$  adipocytokines  $\rightarrow$  increase in BMD<sup>5</sup>
    - T1DM patients  $\rightarrow$  lower BMI lower adipose tissues  $\rightarrow$  more prone to develop OP<sup>5</sup>
  - Poor glycemic control<sup>6</sup>
    - T1DM  $\rightarrow$  poor glycemic control  $\rightarrow$  microvascular complications (Retinopathy, Neuropathy, Nephropathy)
    - Retinopathy and neuropathy  $\rightarrow$  fall  $\rightarrow$  fractures
    - Nephropathy Hypercalciuria AND alter vitamin D metabolism vitamin D deficiency
  - Endocrine factors<sup>7</sup>



## CONCLUSIONS

- Both men and women with T1DM have preponderance to have lower BMD levels
- Multiple factors can influence BMD in individuals with T1DM:
  - Age
  - Gender
  - Menopausal status
  - Bone type
- Large prospective epidemiological studies are required to confirm our findings

## REFERENCES

- Dhaon P and Shah VN. *Indian J Endocrinol Metab.* 2014 Mar-Apr; 18(2): 159–165
- Eller-Vainicher C et al. *Diabetes Care* 34:2186–2191, 2011
- Roggen I et al. *Horm Res Paediatr.* 2013; 79(2):68-74
- Hadjidakis DJ et al. *J Diabetes Complications.* 2006 Sep-Oct; 20(5):302-7
- Hofbauer LC et al. *J Bone Miner Res.* 2007 Sep; 22(9):1317-28
- Joshi A et al. *J Osteoporos.* 2013; 2013():397814
- Thalassinis NC et al. *Diabet Med.* 1993 May; 10(4):341-4